Oxolinic acid
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Oxolinic acid
- DrugBank Accession Number
- DB13627
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Oxolinic acid (DB13627)
- Weight
- Average: 261.2301
Monoisotopic: 261.063722467 - Chemical Formula
- C13H11NO5
- Synonyms
- ácido oxolínico
- Oxolinic acid
- External IDs
- NSC-110364
- W 4565
- W-4565
Pharmacology
- Indication
Not Available
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset- Contraindications & Blackbox Warnings
Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcarbose The therapeutic efficacy of Acarbose can be increased when used in combination with Oxolinic acid. Acebutolol The risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Acebutolol. Aceclofenac Aceclofenac may increase the neuroexcitatory activities of Oxolinic acid. Acemetacin Acemetacin may increase the neuroexcitatory activities of Oxolinic acid. Acenocoumarol The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Oxolinic acid. Acetohexamide The therapeutic efficacy of Acetohexamide can be increased when used in combination with Oxolinic acid. Acetylsalicylic acid Acetylsalicylic acid may increase the neuroexcitatory activities of Oxolinic acid. Acrivastine The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Oxolinic acid. Adenosine The risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Adenosine. Ajmaline The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Oxolinic acid. 
Improve patient outcomesBuild effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.Learn more - Food Interactions
- Not Available
Products
Comprehensive & structured drug product infoFrom application numbers to product codes, connect different identifiers through our commercial datasets.Easily connect various identifiers back to our datasets
Categories
- ATC Codes
- J01MB05 — Oxolinic acid
- Drug Categories
- 4-Quinolones
- Anti-Bacterial Agents
- Anti-Infective Agents
- Anti-Infective Agents, Urinary
- Antibacterials for Systemic Use
- Antiinfectives for Systemic Use
- Antineoplastic Agents
- Enzyme Inhibitors
- Fluoroquinolones
- Heterocyclic Compounds, Fused-Ring
- Potential QTc-Prolonging Agents
- QTc Prolonging Agents
- Quinolines
- Quinolones
- Renal Agents
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at one or more positions.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Quinolines and derivatives
- Sub Class
- Quinoline carboxylic acids
- Direct Parent
- Quinoline carboxylic acids
- Alternative Parents
- Hydroquinolones / Hydroquinolines / Pyridinecarboxylic acids / Benzodioxoles / Benzenoids / Vinylogous amides / Heteroaromatic compounds / Acetals / Azacyclic compounds / Oxacyclic compounds show 6 more
- Substituents
- Acetal / Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Benzodioxole / Carboxylic acid / Carboxylic acid derivative / Dihydroquinoline / Dihydroquinolone / Heteroaromatic compound show 14 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- organic heterotricyclic compound, oxacycle, quinolone antibiotic, quinolinemonocarboxylic acid, aromatic carboxylic acid (CHEBI:138856) / Quinone fungicides (C11342)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- L0A22B22FT
- CAS number
- 14698-29-4
- InChI Key
- KYGZCKSPAKDVKC-UHFFFAOYSA-N
- InChI
- InChI=1S/C13H11NO5/c1-2-14-5-8(13(16)17)12(15)7-3-10-11(4-9(7)14)19-6-18-10/h3-5H,2,6H2,1H3,(H,16,17)
- IUPAC Name
- 5-ethyl-8-oxo-2H,5H,8H-[1,3]dioxolo[4,5-g]quinoline-7-carboxylic acid
- SMILES
- CCN1C=C(C(O)=O)C(=O)C2=CC3=C(OCO3)C=C12
References
- General References
- Not Available
- External Links
- KEGG Drug
- D02301
- KEGG Compound
- C11342
- ChemSpider
- 4467
- 7798
- ChEBI
- 138856
- ChEMBL
- CHEMBL416755
- ZINC
- ZINC000000001875
- PDBe Ligand
- OXI
- Wikipedia
- Oxolinic_acid
- PDB Entries
- 1kse
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Capsule Tablet Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 1.91 mg/mL ALOGPS logP 0.86 ALOGPS logP 1.35 ChemAxon logS -2.1 ALOGPS pKa (Strongest Acidic) 5.58 ChemAxon pKa (Strongest Basic) -4.3 ChemAxon Physiological Charge -1 ChemAxon Hydrogen Acceptor Count 6 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 76.07 Å2 ChemAxon Rotatable Bond Count 2 ChemAxon Refractivity 65.84 m3·mol-1 ChemAxon Polarizability 25.52 Å3 ChemAxon Number of Rings 3 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Drug created on June 23, 2017 20:45 / Updated on February 21, 2021 18:54